Literature DB >> 11277926

Monoclonal antibodies to mycobacterial DNA gyrase A inhibit DNA supercoiling activity.

U H Manjunatha1, S Mahadevan, S S Visweswariah, V Nagaraja.   

Abstract

DNA gyrase is an essential type II topoisomerase found in bacteria. We have previously characterized DNA gyrase from Mycobacterium tuberculosis and Mycobacterium smegmatis. In this study, several monoclonal antibodies were generated against the gyrase A subunit (GyrA) of M. smegmatis. Three, MsGyrA:C3, MsGyrA:H11 and MsGyrA:E9, were further analyzed for their interaction with the enzyme. The monoclonal antibodies showed high degree of cross-reactivity with both fast-growing and slow-growing mycobacteria. In contrast, none recognized Escherichia coli GyrA. All the three monoclonal antibodies were of IgG1 isotype falling into two distinct types with respect to epitope recognition and interaction with the enzyme. MsGyrA:C3 and MsGyrA:H11 IgG, and their respective Fab fragments, inhibited the DNA supercoiling activity catalyzed by mycobacterial DNA gyrase. The epitope for the neutralizing monoclonal antibodies appeared to involve the region towards the N-terminus (residues 351-415) of the enzyme in a conformation-dependent manner. These monoclonal antibodies would serve as valuable tools for structure-function analysis and immunocytological studies of mycobacterial DNA gyrase. In addition, they would be useful for designing peptide inhibitors against DNA gyrase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11277926     DOI: 10.1046/j.1432-1327.2001.02077.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

1.  Characterization of monoclonal antibodies against altered (T103I) amidase from Pseudomonas aeruginosa.

Authors:  Sónia Martins; Amin Karmali; Jorge Andrade; Ana Custódio; Maria Luísa Serralheiro
Journal:  Mol Biotechnol       Date:  2005-07       Impact factor: 2.695

2.  Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase.

Authors:  U H Manjunatha; M Dalal; M Chatterji; D R Radha; S S Visweswariah; V Nagaraja
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

3.  Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis.

Authors:  Ujjini H Manjunatha; Helena Boshoff; Cynthia S Dowd; Liang Zhang; Thomas J Albert; Jason E Norton; Lacy Daniels; Thomas Dick; Siew Siew Pang; Clifton E Barry
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-30       Impact factor: 11.205

4.  An orphan gyrB in the Mycobacterium smegmatis genome uncovered by comparative genomics.

Authors:  P Jain; V Nagaraja
Journal:  J Genet       Date:  2002-12       Impact factor: 1.166

5.  Cyclic AMP in mycobacteria: characterization and functional role of the Rv1647 ortholog in Mycobacterium smegmatis.

Authors:  Bob Kennedy M Dass; Ritu Sharma; Avinash R Shenoy; Rohini Mattoo; Sandhya S Visweswariah
Journal:  J Bacteriol       Date:  2008-04-04       Impact factor: 3.490

6.  Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum.

Authors:  Amit Roy; Ilda D'Annessa; Christine J F Nielsen; David Tordrup; Rune R Laursen; Birgitta Ruth Knudsen; Alessandro Desideri; Felicie Faucon Andersen
Journal:  Mol Biol Int       Date:  2011-05-04

7.  A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism.

Authors:  Ujjini H Manjunatha; Anthony Maxwell; Valakunja Nagaraja
Journal:  Nucleic Acids Res       Date:  2005-06-01       Impact factor: 16.971

8.  Glutamate racemase from Mycobacterium tuberculosis inhibits DNA gyrase by affecting its DNA-binding.

Authors:  Sugopa Sengupta; Meera Shah; Valakunja Nagaraja
Journal:  Nucleic Acids Res       Date:  2006-10-04       Impact factor: 16.971

9.  The importance of perseverance, pilot studies and the search for effective adjuvant therapies in the management of tuberculous pericarditis.

Authors:  Arthur Mutyaba; Mpiko Ntsekhe
Journal:  Cardiovasc J Afr       Date:  2016 Nov/Dec       Impact factor: 1.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.